View in EDS

Targeting Siglec-sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma.

Saved in:
Bibliographic Details
Title: Targeting Siglec-sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma.
Authors: Ray A; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Buon L; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Wan X; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Du T; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Song Y; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Pillai SC; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Musa MA; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Fang T; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Wang M; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Anderson KC; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Source: Blood advances [Blood Adv] 2025 Oct 14; Vol. 9 (19), pp. 5085-5090.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40311068
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Targeting Siglec-sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ray+A%22">Ray A</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Buon+L%22">Buon L</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wan+X%22">Wan X</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Du+T%22">Du T</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Song+Y%22">Song Y</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Pillai+SC%22">Pillai SC</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Musa+MA%22">Musa MA</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Fang+T%22">Fang T</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wang+M%22">Wang M</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Anderson+KC%22">Anderson KC</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2025 Oct 14; Vol. 9 (19), pp. 5085-5090.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40311068
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2025015980
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 5085
    Titles:
      – TitleFull: Targeting Siglec-sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ray A
      – PersonEntity:
          Name:
            NameFull: Buon L
      – PersonEntity:
          Name:
            NameFull: Wan X
      – PersonEntity:
          Name:
            NameFull: Du T
      – PersonEntity:
          Name:
            NameFull: Song Y
      – PersonEntity:
          Name:
            NameFull: Pillai SC
      – PersonEntity:
          Name:
            NameFull: Musa MA
      – PersonEntity:
          Name:
            NameFull: Fang T
      – PersonEntity:
          Name:
            NameFull: Wang M
      – PersonEntity:
          Name:
            NameFull: Anderson KC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 10
              Text: 2025 Oct 14
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 19
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1